Glucophage's Glory comes to an end...
Executive Summary
All too soon after losing its patents on paclitaxel (Taxol), the $1.7 billion breast cancer drug, Bristol-Myers Squibb may be in for another battering. This time its metformin (Glucophage), the company's $1.3 billion oral diabetes drug, which holds 35% share of the US oral diabetes market, has been vulnerable to generic attack since September.